Brugada syndrome (BS) and complete right bundle-branch block (CRBBB) can coexist. CRBBB can completely mask BS, but simultaneous diagnosis has never been attempted. This study represents the first series describing this phenomenon. In 11 patients who had BS and CRBBB, BS was diagnosed before the development of CRBBB, on the resolution of CRBBB, or from new characteristic ST-segment changes that could be attributable to BS. The QRS duration was more prolonged and the amplitude of R in V 1 was larger in the patients with BS and CRBBB compared with age-and sexmatched control subjects. In BS patients with CRBBB, relief of CRBBB, repeated ECG recordings, or pharmacological tests can be useful to demonstrate typical ST-segment elevation. The prevalence, mechanism, and clinical significance of the combination of CRBBB and BS need to be determined.
The risk of stent thrombosis, a life-threatening complication of stent placement, is reduced by antiplatelet therapy combining aspirin and a P2Y 12 platelet receptor antagonist such as clopidogrel. When platelet inhibition is inadequate, the risk increases. Clopidogrel produces moderate and variable P2Y 12 inhibition. Ticagrelor, a reversibly acting nonthienopyridine P2Y 12 antagonist that provides more potent and consistent platelet inhibition, was compared with clopidogrel in patients with acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial and reduced the primary outcome of cardiovascular death, myocardial infarction, and stroke, as well as cardiovascular mortality. This analysis describes the effects of ticagrelor compared with clopidogrel on the risk of stent thrombosis in patients with stents in the PLATO trial. Of 18 624 patients hospitalized for acute coronary syndromes, 61% had at least 1 intracoronary stent and were analyzed. Ticagrelor reduced definite stent thrombosis compared with clopidogrel (hazard ratio, 0.67; 95% confidence interval, 0.50-0.90; P=0.0091) but also definite or probable and any stent thrombosis. The reduction in definite stent thrombosis was consistent regardless of acute coronary syndromes type, the presence of diabetes mellitus, stent type (drug-eluting or bare metal stent), CYP2C19 genetic status, loading dose of aspirin, dose of clopidogrel before randomization, and use of glycoprotein IIb/IIIa inhibitors at randomization. Randomization to ticagrelor was a strong independent inverse predictor of definite stent thrombosis in multivariable Cox regression analyses. Ticagrelor compared with clopidogrel reduced the incidence of stent thrombosis in acute coronary syndromes patients across a broad range of patient, stent, and treatment characteristics. See p 1055.
Inhibition of MicroRNA-92a Protects Against Ischemia/ Reperfusion Injury in a Large-Animal Model
Although revascularization of an infarct-related artery is state-of-the-art treatment of acute coronary syndromes, ischemia/reperfusion induces cellular stress and damage, potentially inflicting organ dysfunction. Treatment options are required to simultaneously prevent cardiomyocyte damage, endothelial dysfunction, and overwhelming postischemic inflammation. MicroRNA (miR) inhibition might meet these requirements because miRs target multiple signaling pathways, thereby providing pleiotropic effects. miR-92a, a member of the miR17-92 cluster, is upregulated after acute myocardial infarction, and its inhibition enhanced neovascularization in a murine infarct model. Here, we demonstrate that regional miR-92a inhibition via locked nucleic acidmodified antisense miR-92a (LNA-92a) improved cardiac function and reduced ischemia/reperfusion-induced cardiomyocytic cell death, endothelial dysfunction, and inflammation. Regional application of LNA-92a might offer a novel therapeutic option to improve cardiac function after acute myocardial ischemia/reperfusion injury. See p 1066.
Interpretation of the Coronary Artery Calcium Score in Combination With Conventional Cardiovascular Risk Factors: The Multi-Ethnic Study of Atherosclerosis (MESA)
The coronary artery calcium score is a strong predictor of coronary heart disease events, but it is not always clear how to interpret the score in the context of a patient's conventional coronary heart disease risk factors, such as blood pressure, cholesterol, and smoking status. This analysis of the Multi-Ethnic Study of Atherosclerosis (MESA) provides a way for clinicians to use conventional coronary heart disease risk factor information about a patient to understand how high a coronary artery calcium score to expect. When the actual score is higher than expected, a clinician's estimate of that patient's coronary heart disease risk (the "pretest" risk; eg, from Framingham equations), should be adjusted upward; if it is lower than expected, the clinician's estimate should be revised downward. This article describes a method for making this adjustment and provides examples to illustrate the importance of individualized interpretation of the coronary artery calcium score. These methods may be useful for clinicians in deciding when to order a coronary artery calcium score and how to interpret the results. See p 1076.
Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction: A Community-Based Study
Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are burgeoning and commonly coexistent cardiovascular epidemics of an aging population. Although previous studies have focused on the association Volume 128 ◼ Number 10 ◼ September 3, 2013
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between prevalent AF and outcomes in HFpEF patients, the predictors and clinical impact of incident AF remain unclear. We examined 939 community-based patients with incident HFpEF from Olmsted County, Minnesota, and evaluated their clinical characteristics and mortality according to the temporal relationship of AF to HFpEF onset. AF occurred prior to (>3 months) or concurrent with (±3 months) HFpEF diagnosis in 52% of the HFpEF patients and was associated with older age, higher levels of brain-type natriuretic peptide, and larger left atrial volume index at HFpEF diagnosis compared with patients in sinus rhythm. Of patients in sinus rhythm at HFpEF diagnosis, 32% developed AF over a median follow-up of 3.7 years. Age and diastolic dysfunction were positively associated with incident AF, whereas HFpEF patients on statin therapy were significantly less likely to develop AF. Prevalent AF and incident AF were associated with a higher risk of all-cause mortality compared with HFpEF patients in sinus rhythm. Incident AF was associated with the highest risk for death. AF is common in the natural history of HFpEF and confers a poor prognosis. Future studies are required to determine whether intervention for AF may improve outcomes or if statin use can prevent AF in HFpEF. See p 1085.
Restriction of Calpain3 Expression to the Skeletal Muscle Prevents Cardiac Toxicity and Corrects Pathology in a Murine Model of Limb-Girdle Muscular Dystrophy
Gene therapy is the process to introduce a gene into an individual's tissues to treat a disease such a hereditary disease or cancer. Even if it is still in its infancy, scientific breakthroughs continue to move this strategy toward practical medicine. In this work, we described for the first time the association of a lethal cardiac toxicology with an experimental gene transfer approach. Indeed, we showed that gene transfer of calpain3, a muscle-specific protease implicated in limb-girdle muscular dystrophy 2A, led to mortality in mice that we related to expression and unregulated activity of the protease in the cardiac tissue. Following this observation, we developed and tested several approaches that were efficient to prevent this toxicity while preserving the therapeutic effect. The presented molecular strategies may be useful for any gene transfer approach with potential toxicity in the heart and may therefore have an impact related to the safety of gene therapy. See p 1094.
Subclinical Left Ventricular Dysfunction and Silent Cerebrovascular Disease: The Cardiovascular Abnormalities and Brain Lesions (CABL) Study
In population studies, the prevalence of silent brain infarcts has been estimated from 7% to 28%, depending on the age of the studied population. Cerebral white matter hyperintensity volume has also been described in asymptomatic participants in population studies. Both silent brain infarct and white matter hyperintensity volume have been associated with future incidence of stroke, cognitive impairment, and dementia. We conducted a study in a stroke-free community-based cohort without overt cardiac disease from the Cardiac Abnormalities and Brain Lesions (CABL) study to assess the relationship between left ventricular (LV) systolic function measured by speckle-tracking global longitudinal strain and subclinical brain disease. For the first time, we showed that an abnormal global longitudinal strain was associated with an >3-fold increase in risk of having a silent brain infarct and a higher white matter hyperintensity volumes, and these associations were independent of LV ejection fraction and other confounders. The traditional assessment of LV systolic function by LV ejection fraction was not associated with subclinical cerebrovascular disease. Our findings suggest that measuring global longitudinal strain, even in a population without overt cardiovascular disease, may allow early identification of subjects with subclinical LV dysfunction who might also be at higher risk of developing cerebrovascular disease. Whether targeted treatment strategies and risk factor control may reduce the future incidence of clinical stroke and cognitive decline in those individuals needs further study. See p 1105.
